🎉 Celebrating Promotion in Pharmidex! 🌟
March 10, 2025

Pharmidex is thrilled to announce the well-deserved promotion of our talented Bioanalyst, Alix Hampson, to Head of Bioanalysis! 👏🎊 Alix’s dedication, expertise, and passion for scientific excellence have made a significant impact, and we couldn’t be prouder to see her take on this leadership role.


This achievement is even more special as we celebrate International Women’s Day, a moment to recognize and honor the incredible contributions of women in science and drug discovery.


At Pharmidex, we are committed to fostering a culture where women thrive, lead, and shape the future of innovation. 

We would also like to take this opportunity to celebrate the dedication and invaluable contributions of all the incredible women at Pharmidex, your hard work, talent, and commitment continue to drive our success every day. 💪💜


Here’s to Alix and all the brilliant women driving progress in science! 💜🚀

#WomenInScience #IWD2025 #Pharmidex #DrugDiscovery #Leadership #WomenInSTEM #CelebratingSuccess

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts